ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,777.15
      0.17%
      US Tech 100
      19,677.22
      0.26%
      Dow Jones
      42,673.86
      0.21%
      Brent Oil
      72.925
      0.54%
      Bitcoin
      87,932.61
      0.47%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. AN2 Therapeutics Inc (ANTX) Quote

      AN2 Therapeutics Inc

      AN2 Therapeutics Inc (ANTX)

      NASDAQ
      1.51
      0.06
      (4.14%)
      Closed March 24 4:00PM
      Delayed by 15 minutes
      1.51
      0.00
      ( 0.00% )
      Pre Market: 6:11AM
      Delayed by 15 minutes
      Advanced chart

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.51
      Bid
      1.35
      Ask
      1.53
      Volume
      10
      0.00 Day's Range 0.00
      0.87 52 Week Range 3.88
      Market Cap
      45.117M
      Previous Close
      1.51
      Open
      -
      Last Trade
      10
      @
      1.52
      Last Trade Time
      06:11:58
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      130,648
      Shares Outstanding
      29,878,890
      Dividend Yield
      -
      PE Ratio
      -0.70
      Earnings Per Share (EPS)
      -2.17
      Revenue
      -
      Net Profit
      -64.73M

      About AN2 Therapeutics Inc

      AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.an2therapeutics.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was $1.51. Over the last year, AN2 Therapeutics shares have traded in a share price range of $ 0.87 to $ 3.88.

      AN2 Therapeutics currently has 29,878,890 shares outstanding. The market capitalization of AN2 Therapeutics is $45.12 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.70.

      Ask ADVFN Intelligence (AI)

      ANTX Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 28 2025
      ANTX (4.14%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 28 2025
      ANTX (4.14%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 28 2025
      ANTX (4.14%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 28 2025
      ANTX (4.14%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 07 2025
      ANTX (4.14%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.140510.2592186931.36951.52251.3695638931.46567885CS
      40.3833.62831858411.131.52251.0851197251.2550971CS
      120.117.857142857141.41.52251.04991306481.2163258CS
      260.4542.45283018871.061.6750.9753133971.2253932CS
      52-1.82-54.65465465473.333.880.873632331.46535507CS
      156-15.34-91.038575667716.8523.580.871903324.35200872CS
      260-15.34-91.038575667716.8523.580.871903324.35200872CS

      ANTX - Frequently Asked Questions (FAQ)

      What is the current AN2 Therapeutics share price?
      The current share price of AN2 Therapeutics is $ 1.51
      How many AN2 Therapeutics shares are in issue?
      AN2 Therapeutics has 29,878,890 shares in issue
      What is the market cap of AN2 Therapeutics?
      The market capitalisation of AN2 Therapeutics is USD 45.12M
      What is the 1 year trading range for AN2 Therapeutics share price?
      AN2 Therapeutics has traded in the range of $ 0.87 to $ 3.88 during the past year
      What is the PE ratio of AN2 Therapeutics?
      The price to earnings ratio of AN2 Therapeutics is -0.7
      What is the reporting currency for AN2 Therapeutics?
      AN2 Therapeutics reports financial results in USD
      What is the latest annual profit for AN2 Therapeutics?
      The latest annual profit of AN2 Therapeutics is USD -64.73M
      What is the registered address of AN2 Therapeutics?
      The registered address for AN2 Therapeutics is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
      What is the AN2 Therapeutics website address?
      The website address for AN2 Therapeutics is www.an2therapeutics.com
      Which industry sector does AN2 Therapeutics operate in?
      AN2 Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 76.9699
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.05
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.99
      (0.00%)
      		184
      AACBUArtius II Acquisition Inc
      $ 10.04
      (0.00%)
      		1
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 76.9699
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.05
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.99
      (0.00%)
      		184
      AACBUArtius II Acquisition Inc
      $ 10.04
      (0.00%)
      		1
      TNONTenon Medical Inc
      $ 0.9781
      (0.00%)
      		121.17M
      BONBon Natural Life Ltd
      $ 0.1491
      (0.00%)
      		68.38M
      POAIPredictive Oncology Inc
      $ 1.115
      (0.00%)
      		65.68M
      MULNMullen Automotive Inc
      $ 0.2558
      (0.00%)
      		58.29M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 11.16
      (0.00%)
      		34.24M

      ANTX Financials

      Financials

      ANTX Discussion

      View Posts
      glenn1919 glenn1919 3 months ago
      ANTX.....................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 3 months ago
      ANTX........................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
      👍️0
      TrendTrade2016 TrendTrade2016 4 months ago
      ANTX NEXT WEEK WATCH
      👍️0
      stocksrising stocksrising 4 months ago
      Open market purchase always welcomed :)..even if tiny 😜

      Common Stock-CEO
      11/18/2024
      50,000
      A
      $0.9994
      1,065,76
      👍️0
      TrendTrade2016 TrendTrade2016 4 months ago
      ANTX MINI BIO BEAST
      👍️ 1
      stocksrising stocksrising 4 months ago
      I haven’t done much DD on this bio, but it seems they have several readouts within 6-12mos. that could propel stock higher (especially with the $$$ runway position)… as you know, any biotech is risky but I like the odds on this one and starter position is small for now…I did copy this from release that I found appealing:

      Boron Chemistry Pipeline

      Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025.

      Global Health

      In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding.
      👍️0
      eyeownu eyeownu 4 months ago
      NOPE. took my looses moved them over to $EBS and made it all back. do you notice anything promising that warrants investing in this company besides the cash on hand?
      👍️0
      stocksrising stocksrising 4 months ago
      Picked up a bit more down here at $1ish, you still in??
      👍️0
      Monksdream Monksdream 7 months ago
      ANTX new 52 week low
      👍️0
      Monksdream Monksdream 8 months ago
      ANTX under $3
      👍️0
      eyeownu eyeownu 8 months ago
      looking good
      👍️0
      glenn1919 glenn1919 9 months ago
      ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 12 months ago
      FROM 3/28 NEWS:

      Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

      GO4AWILDRIDE
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 12 months ago
      THE FOLLOWING FROM THE 3/28 NEWS:

      “AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

      GO4AWILDRIDE
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 12 months ago
      Monksdream

      Did you read the 3/28 news from the compay?

      Seems like the market is looking to chase the price up.

      GLTU

      GO4AWILDRIDE
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 12 months ago
      Monksdream

      Seems like a nice rebound is starting to occur.

      GLTU

      GO4AWILDRIDE
      👍️0
      Monksdream Monksdream 1 year ago
      ANTX new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      ANTX new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      ANTX new 52 week low
      👍️0

      Your Recent History

      NASDAQ
      ANTX
      AN2 Therapeutics
      BIT
      1LEVI
      Levi Strauss &
      BIT
      UC0JMX
      Unicredit Bank
      BIT
      UB514T
      Unicredit Bank
      BIT
      UC0SEZ
      Unicredit Bank
      BIT
      UC8HX2
      Unicredit Bank
      BIT
      UB8HS0
      Unicredit Bank
      BIT
      UC16ZT
      Unicredit Bank
      BIT
      UC63GW
      Unicredit Bank
      BIT
      UC2V5U
      Unicredit Bank
      BIT
      UC3JQS
      Unicredit Bank
      BIT
      UC839B
      Unicredit Bank
      BIT
      UC0462
      Unicredit Bank
      BIT
      Q00458
      Leonteq Securities
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads